Literature DB >> 6414355

Clomiphene-responsive hypogonadism in sickle cell anemia.

C S Landefeld, M Schambelan, S L Kaplan, S H Embury.   

Abstract

Two 19-year-old men with sickle cell anemia and hypogonadism had hypothalamic dysfunction that responded to oral clomiphene therapy. The patients had no nutritional deficiencies or anatomic lesions known to result in the hypogonadism associated with sickle cell anemia. Their sickle cell disease was characterized by infrequent crises, severe hemolytic anemia, urinary iron loss, and iron deficiency. Partial hypothalamic hypogonadism was shown by low levels of testosterone, low to low-normal levels of luteinizing hormone and follicle-stimulating hormone, and a nearly normal rise in gonadotropin levels in response to exogenous gonadotropin releasing hormone. Treatment with oral clomiphene raised luteinizing hormone, follicle-stimulating hormone, and testosterone levels to normal, and induced puberty in both patients. Treatment was discontinued in one patient because of the onset of priapism, but was continued for 10 months without side effects in the other. Severe hypogonadism in patients with sickle cell anemia should be thoroughly evaluated and clomiphene therapy considered in patients with hypothalamic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414355     DOI: 10.7326/0003-4819-99-4-480

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  2 in total

1.  Testicular dysfunction in men with sickle cell disease.

Authors:  D N Osegbe; O O Akinyanju
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

2.  Sickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia.

Authors:  Mário Angelo Claudino; Kleber Yotsumoto Fertrin
Journal:  Anemia       Date:  2012-06-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.